JFD01307SC|CAS 51070-56-5|DC Chemicals

Cas No.:	51070-56-5
Chemical Name:	Glycine,N-(tetrahydro-1,1-dioxido-3-thienyl)-
Synonyms:	Glycine,N-(tetrahydro-1,1-dioxido-3-thienyl)-;(1,1-Dioxotetrahydro-1-lambda6-thiophen-3-yl-amino)acetic acid;(1,1-DIOXO-TETRAHYDRO-THIOPHEN-3-YLAMINO) ACETICACID;[(1,1-DIOXIDOTETRAHYDROTHIEN-3-YL)AMINO]ACETIC ACID;2-[(1,1-dioxothiolan-3-yl)amino]acetic acid;HMS548G19;N-(1,1-dioxidotetrahydrothiophen-3-yl)glycine;N-(Tetrahydro-1,1-dioxido-3-thienyl)-glycine
SMILES:	O=S1(=O)CCC(NCC(O)=O)C1
Formula:	C₆H₁₁NO₄S
M.Wt:	193.22084069252
Purity:	》98%
Sotrage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Description:

JFD01307SC is a glutamine synthetase inhibitor and anti-tuberculosis agent. JFD01307SC acts as a mimic of L-Glutamate and thus target enzymes involved in glutamine biosynthesis.

Cat. No.	Product name	Field of application
DC72952	Savirin	Savirin (S. aureus virulence inhibitor) is a small molecule that targets the agr (accessory gene regulator) quorum sensing system in Staphylococcus aureus (S. aureus). The agr system is a key regulatory pathway that controls the expression of virulence factors in S. aureus, which are critical for its pathogenicity. The system involves a two-component signal transduction pathway consisting of AgrC (a histidine kinase) and AgrA (a response regulator).
DC72935	JSF-2414	JSF-2414 (JSF2414) is a potent, small molecule GyrB/ParE dual binding inhibitor, simultaneously binds to ATP binding regions of DNA gyrase (GyrB) and topoisomerase (ParE) and displays potent in vitro activity against strains of MRSA, VRSA and VISA.
DC72921	COE2-2hexyl	COE2-2hexyl represents an innovative class of antimicrobial agents, demonstrating broad-spectrum antibacterial activity through its unique conjugated oligoelectrolyte (COE) structure.
DC72279	MRV03-070	MRV03-070 is an inhibitor of colibactin-activating peptidase ClbP with an IC50 value of 69 nM, acts like biosynthetic precursor precolibactin.
DC72144	TH-Z145	TH-Z145, a lipophilic bisphosphonate, is a FPPS inhibitor (IC50: 210 nM).
DC71474	VP-4604	VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 µg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95%.
DC71466	EDA-DA	EDA-DA is an unnatural dipeptide building block (an ethynyl-D-alanine and a D-alanine). It incorporates a biorthogonal alkyne group into peptidoglycan (PG) through MurF in the cytoplasmic pathway, which enables selective labeling via a click-chemistry reaction. EDA-DA allows labeling of PG in Gram-positive (B. subtilis), Gram-negative (E. coli and C. trachomatis), Mycobacterium (M. smegmatis) and moss plastids (P. patens) with azide modified fluorescent dyes such as Alexa Fluor 488.
DC70750	Rv1625c agonist V-59	Rv1625c agonist V-59 (V-59) is a specific small molecule agonist of the Mtb adenylyl cyclase Rv1625c, inhibits Mtb growth in macrophages (EC50=0.3 uM) in an Rv1625c-dependent mechanism.V-59 inhibits Mtb growth in cholesterol media (EC50 0.70 uM), but not in media containing the two-carbon fatty acid acetate, or in standard rich growth media.V-59 stimulates Rv1625c to produce cAMP, which is necessary for V-59 to inhibit Mtb growth.Chemically activating Rv1625c via V-59 preferentially inhibits cholesterol utilization in WT Mtb, rather than equally inhibiting all lipid utilization by the bacterium.
DC70591	mCLB073	mCLB073 is an advanced, orally active small molecule agonist specifically designed to target Mtb adenylyl cyclase Rv1625c. As an optimized derivative of V-59, it demonstrates significantly enhanced potency and efficacy for in vivo applications. In cholesterol-based media, mCLB073 shows a remarkable 17-fold increase in activity against Mtb compared to its predecessor, V-59, while retaining favorable pharmacokinetic characteristics and a strong safety profile. In preclinical studies, oral administration of mCLB073 at 30 mg/kg led to a substantial reduction in Mtb colony-forming units (CFUs) in the lungs of mice, accompanied by a 45% decrease in lung pathology severity. These findings highlight its potential as a promising therapeutic candidate for tuberculosis treatment.
DC70585	MBX3132	MBX3132 is a small mocule inhibitor of AcrB multidrug efflux pump, fully potentiates the activity of a broad range of antibiotics at 0.1 uM; does not exhibit membrane-disrupting or antibacterial activity.